Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4929097 in Advanced TNBC
NCT01151449Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2010
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RO4929097 in triple-negative breast cancer (TNBC), sponsored by National Cancer Institute. Primary endpoints: Overall Response Rate and Progression-free Survival at 6 months. Started Jun 2010; status: terminated.
02
Drugs
RO4929097
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01151449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01151449.